Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Metabolomics analysis of Vehicle (DMSO/PBS; (1:1) v/v) and DRB18 (10 mg/kg) treated A549 xenograft tumors

ABSTRACT: A549 xenograft tumors were treated with (DMSO/PBS; (1:1) v/v) and DRB18 (10 mg/kg) for 5 weeks. The mice were then sacrificed and tumors were then excised. Tumors were then subjected to untargeted metabolomics analysis.

ORGANISM(S): Mouse Mus Musculus

TISSUE(S): Tumor Cells

DISEASE(S): Cancer

SUBMITTER: Pratik Shriwas

PROVIDER: ST001638 | MetabolomicsWorkbench | Mon Dec 07 00:00:00 GMT 2020

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptome analysis of xenograft tumors treated with vehicle control or CBL0137

Project description:RNAseq was used to identify host and viral transcriptome changes in xenograft tumors treated with DMSO or CBL0137. Mouse xenograft experiments were regulated by Institutional Animal Care & Use Committee (IACUC# 2017-0035) of Weill Cornell Medical Center(WCMC). Non-obese diabetic/severe combined immunodeficiency (NOD-SCID) mice were obtained from Jackson Laboratories. Six to eight-week-old male and female mice (10 male/18 female) were injected in the flank with 1 x 107 BL cells in PBS with Matrigel eleven days before the treatment. Once the mice developed tumors with the size greater than 300 mm^3, they were grouped randomly and injected with vehicle (5% dextrose), 10mg/kg, or 60mg/kg of CBL0137. One week later, mice were injected with second dose of vehicle or CBL0137. Mice were humanely sacrificed at set experimental timepoints or when tumors reached the institutional cutoff. Tumors were harvested and snap frozen in liquid nitrogen for RNA, DNA, and sectioning for immunohistochemistry. RNAseq experiments were performed with tumor samples from 3 control and 3 60mg/kg CBL0137 treated mice.

2020-04-20 | GSE140652 | GEO

Gene expression of patient derived xenograft glioblastoma treated with DMSO control or Panobinostat.

Project description:Panobinostat is a non-selective histone deactylase inhibitor which has been approved by FDA for treatment of mutiple myeloma. Whether and how the drug works on glioblastoma remains unclear. Here we treated mice implanted with patient derived xenograft glioblastoma G43 with DMSO or Panobinostat and harvest the tumors for microarray analysis for gene expression results.

2019-01-09 | GSE108957 | GEO

RNA-seq data for OMVs@P2O-Ads treated cell derived xenograft and PBS treated cell derived xenograft

Project description:RNA-seq data for OMVs@P2O-Ads treated cell derived xenograft and PBS treated cell derived xenograft

| PRJNA869598 | ENA

Development of gene expression profiles for murine breast tumours treated with Sunitinib

Project description:In order to establish a profile of gene expression of tumours treated with sunitinib, 4T1 breast tumours were allowed to establish in Balb/C mice for 1 week. The mice were then treated with 40 mg/kg Sunitinib in PBS and 3.72% DMSO (treatemt group) or PBS-DMSO vehicle alone (no treatment group), daily for the period of the experiment, after which the tumours were resected homogenised and subjected to CD31 microbead separation of endothelial cells and bulk tissue, both of which were subjected to agilent microarray analysis. Treated tumours greater than 250 mm3 (by caliper measurement) after 8 days of treatment were considered resistant to treatment, those smaller than this were considered sensitive to sunitinib treatment.

2016-07-06 | GSE84048 | GEO

Transcriptomic analysis of E0771 tumors treated with FEC + oHSV-1 Vs PBS

Project description:E0771 tumors were implanted either subcutaneously on the left flank or orthotopically in the mammary fat pad and treated with either PBS or FEC + oHSV-1 Mice were sacrificed 5 days after the start of treatment and whole tumour digests were used for RNA extraction

2021-10-01 | GSE183864 | GEO

DNA Methylome Analysis of Human Cancer Cells with STELLA Protein Overexpression and the Xenograft Tumor Tissues from the Mice Treated by the Indicated LNP Formulations

Project description:Genome-wide DNA methylation profiling of non-small cell lung cancer (NSCLC) cell line A549 and breast cancer cell line MDA-MB-231 stably expressing hSTELLA and mSTELLA, as well as the HCT116 xenograft tumor tissues from the mice treated by the indicated LNP formulations. The Infinium MethylationEPIC v2.0 array was used to obtain DNA methylation profiles across more than 935,000 CpGs in 15 samples. Samples included 3 stable NSCLC cells and 3 stable breast cancer cells expressing the STELLA orthologs, and 9 xenograft tumors from the mice with the indicated treatments.

2024-07-28 | GSE273176 | GEO

Gene expression analysis of Rip1Tag2 spontaneous tumors treated by sEphB4-Alb or PBS

Project description:Rip1Tag2 mice spontaneously develop tumors. Mice were treated with sEphB4-Alb or PBS for 3.5 weeks. RNA was isolated from harvested tumors and subjected to global gene expression analysis.

2010-10-09 | GSE24603 | GEO

Xenograft tumors of neuroblastoma cell lines

Project description:Xenograft tumors of neuroblastoma cell lines

| PRJNA515055 | ENA

Regulation of gene expression in ALK inhibitor CH5424802-treated NCI-H2228 xenograft tumors

Project description:To clarify the downstream signal pathway of EML4-ALK in NSCLC, we performed Affymetrix GeneChip analysis using ALK inhibitor CH5424802-treated NCI-H2228 xenograft tumors, and comprehensively characterized the gene expression regulated by inhibition of activated ALK. Mice bearing NCI-H2228 cells were orally administered at dose of 0 (vehicle), 4 or 20 mg/kg of CH5424802, and the tumors were collected and lysed at 6 hours post-dose. Total RNA were extracted from xenograft tumors.

2011-06-03 | E-GEOD-25118 | biostudies-arrayexpress

Concomitant targeting of viral and host methyltransferases is essential for attenuating SARS-CoV-2

Project description:LC-MS/MS based investigation of protein abundance changes, induced by DZNep treatment in A549-ACE2 cell line (0.75 uM DZNep, vehicle PBS; 6h pre-treatment, harvested 24 h.p.i. with mock/SARS-CoV/SARS-CoV-2 at MOI 3) or primary human bronchial epithelial cells (NHBEs) (1.5 uM DZNep, vehicle PBS; 6h pre-treatment, harvested 36 h.p.i. with mock/SARS-CoV/SARS-CoV-2 at MOI 3), or by Tubercidin in A549-ACE2 cell line (1 uM Tubercidin, vehicle DMSO; 3h pre-treatment, harvested 24 h.p.i. with mock/SARS-CoV at MOI 0.01/SARS-CoV-2 at MOI 0.1).

2022-06-28 | PXD034361 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data